Switch to
More onapp

Vanta Bioscience Ltd

VANTABIO
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹46 cr, stock is ranked 2,673
High RiskStock is 4.25x as volatile as Nifty
80.002.55 (+3.29%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareLabs & Life Sciences Services
SmallcapWith a market cap of ₹46 cr, stock is ranked 2,673
High RiskStock is 4.25x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
582.68
PB RatioPB Ratio
1.78
Dividend YieldDiv. Yield
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Vanta Bioscience Limited is an India-based is a preclinical contract research company. The Company is engaged in research and development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies, as well as diagnostics and cosmetics, including clinical research. It provides risk assessment services for evaluating the safety of the active pharmaceutical ingredients (API), excipients, extractable and leachable, including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. It also provides expert services for determination of health-based exposure limits, such as permitted daily exposure (PDE) or allowable daily exposure (ADE), including occupational exposure limits (OEL) for pharmaceutical manufacturers. The Company's subsidiaries include Vanta Clinical Research Limited and Vayam Research Solutions Limited.

Financial TrendFinancial statements 

201920202021202212.6514.2510.0710.110.701.000.450.08
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Company Update 
Announced OnNov 27, 2022

Vanta Bioscience Ltd - 540729 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) | Download

Vanta Bioscience Ltd - 540729 - Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) | Download

Board Meeting 
Announced OnNov 8, 2022

Vanta Bioscience Ltd - 540729 - Board Meeting Intimation for Approval Of Unaudited Financials (Standalone & Consolidation) For The Half Year Ended 30.09.2022 | Download

Vanta Bioscience Ltd - 540729 - Board Meeting Intimation for Approval Of Unaudited Financials (Standalone & Consolidation) For The Half Year Ended 30.09.2022 | Download

See all events